Comparative Pharmacology
Head-to-head clinical analysis: LEVATOL versus NEBIVOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVATOL versus NEBIVOLOL HYDROCHLORIDE.
LEVATOL vs NEBIVOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a nonselective beta-adrenergic antagonist with additional alpha1-adrenergic blocking activity. It competitively blocks beta1 and beta2 receptors and alpha1 receptors, leading to decreased heart rate, myocardial contractility, and systemic vascular resistance.
Selective beta-1 adrenergic receptor antagonist with nitric oxide-mediated vasodilatory activity via stimulation of beta-3 receptors.
50 mg orally once daily, increasing to 100 mg once daily after 2 weeks if tolerated; maximum 200 mg once daily.
5 mg orally once daily. May be initiated at 2.5 mg in patients with renal impairment or those at risk of hypotension. Titrate at 2-week intervals up to 40 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours; prolonged to 10-16 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 12-19 hours in extensive metabolizers; up to 30-50 hours in poor CYP2D6 metabolizers; clinically, once-daily dosing is effective due to pharmacodynamic half-life >40 hours.
Renal excretion accounts for 55-60% as unchanged drug; biliary/fecal elimination accounts for 40-45% as metabolites and unchanged drug.
Approximately 38% renal, 48% fecal (unchanged drug and metabolites); extensive hepatic metabolism (CYP2D6) with glucuronidation; <1% excreted unchanged in urine.
Category C
Category A/B
Beta-Blocker
Beta-Blocker